Bausch Health Companies

Synergetics USA, Inc. is a medical device company headquartered in O'Fallon, Missouri, specializing in precision surgical devices and equipment primarily for the ophthalmology and neurosurgery markets. The company offers around 1,000 products, including disposable and reusable devices, surgical equipment, and procedural kits that utilize various energy modalities, such as laser, ultrasonic, and radio frequency energy. Notable products include the VersaVIT 2.0 vitrectomy system, procedural packs under the VersaPACK and Core Essentials brands, fiberoptic endoilluminators, and endolaser probes. Additionally, Synergetics USA provides illumination equipment and laser systems tailored for the U.S. market. Its products are sold directly as well as through distributors and independent sales representatives, targeting end-users in hospitals, ambulatory surgery centers, and surgical offices. The company has been in operation since 1991 and functions as a subsidiary of Valeant Pharmaceuticals International.

Sprout Pharmaceuticals, Inc. is a medical company focused on developing treatments for female sexual health, particularly addressing female sexual dysfunction. Founded in 2011 and based in Raleigh, North Carolina, the company is known for its product, Addyi, a non-hormonal pill designed to treat acquired and generalized hypoactive sexual desire disorder in premenopausal women. This medication aims to alleviate distress related to low libido and enhance the frequency of satisfying sexual experiences. Sprout Pharmaceuticals is dedicated to advancing women's sexual health and has emerged as a significant player in this field.

Amoun Pharmaceutical Company S.A.E. is engaged in the development, manufacturing, marketing, and distribution of a diverse range of human pharmaceutical and animal health products, primarily in Egypt. Established in 1998 and headquartered in Cairo, the company exports its products to around 28 countries across the Middle East, Africa, Asia, and Europe. Amoun's extensive product portfolio addresses various therapeutic needs, including treatments for high-prevalence diseases and conditions of national interest. The company maintains a strong pipeline, with over 30 new products at various stages of registration, aimed at meeting unmet healthcare demands. By focusing on quality healthcare solutions, Amoun Pharmaceutical is positioned to contribute significantly to the health sector while driving growth and enhancing value for its stakeholders.

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs for gastrointestinal diseases in the United States. Founded in 1989 and headquartered in Raleigh, North Carolina, the company offers a range of products, including Xifaxan for hepatic encephalopathy and traveler's diarrhea, Apriso for ulcerative colitis, and Moviprep for colon cleansing prior to colonoscopy. Salix’s portfolio also includes treatments for opioid-induced constipation, fecal incontinence, and various gastrointestinal conditions such as gastroesophageal reflux disease and hypertriglyceridemia. Additionally, the company provides products for managing symptoms related to HIV/AIDS treatments and renal transplantation. Salix Pharmaceuticals has been dedicated to delivering effective solutions for healthcare providers and patients in the realm of gastroenterology for over two decades. As of April 2015, it operates as a subsidiary of Valeant Pharmaceuticals International.

Dendreon is a Seattle-based biotechnology company dedicated to transforming cancer treatment through the discovery, development, and commercialization of innovative therapeutics. The company specializes in Active Cellular Immunotherapy (ACI), utilizing its expertise in antigen identification, engineering, and cell processing to create product candidates that aim to stimulate the immune system's response to cancer. ACI has the potential to provide significant clinical benefits, such as increased survival rates, while minimizing toxicity. In addition to its ACI offerings, Dendreon is also developing an orally-available small molecule that targets TRPM8, which may have applications in various cancer types as well as benign prostatic hyperplasia. The company focuses on reprogramming the body's immune cells to recognize and attack cancer cells, thereby improving patient outcomes with a reduced impact on healthy tissues.

Valeo Medical, Inc., a life sciences company, develops a non-invasive diagnostic blood test for endometriosis. The company was founded in 2003 and is based in Burlington, Massachusetts. Valeo raised money as part of the Discovery Life Sciences fund which was partly funded by the Nashville Capital Network.

PreCision Dermatology is a rapidly growing company dedicated to advancing skincare through innovative therapies. It focuses on developing products that enhance the delivery of active ingredients to the skin, reducing side effects and strengthening the skin's natural barrier. The company's portfolio addresses various dermatological conditions like atopic dermatitis, acne, and rosacea. PreCision Dermatology expands its offerings through internal research, acquisitions, licensing agreements, and strategic partnerships.

Solta Medical, Inc. is a medical device company specializing in energy-based systems for aesthetic applications. Founded in 1995 and headquartered in Hayward, California, the company designs, develops, and manufactures a range of products for skin rejuvenation and body contouring. Notable offerings include the Thermage NXT system, which provides non-invasive skin tightening and cellulite enhancement, as well as the Fraxel re:fine, re:store, and re:pair systems, which address various skin conditions such as fine lines, pigmentation, acne scars, and deeper wrinkles. These systems comprise handpieces, a user-friendly console, an energy source, and disposable treatment tips. Solta Medical serves a diverse clientele, including dermatologists, plastic surgeons, and gynecologists, and distributes its products through a direct sales force and a network of distributors both in the United States and internationally. The company was previously known as Thermage, Inc. before rebranding to Solta Medical in January 2009.

Bausch + Lomb is a prominent global eye health business dedicated to enhancing and protecting vision for people at all life stages. With a comprehensive portfolio exceeding 400 products, the company offers a wide range of solutions, including contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, and surgical devices. It operates in three primary segments: vision care, surgical, and ophthalmic pharmaceuticals. The vision care segment includes contact lenses, where the company holds a notable market share, as well as ocular health products such as Biotrue and Lumify. The surgical segment provides essential tools and technologies for cataract and vitreoretinal surgeries, including intraocular lenses and surgical instruments. Additionally, the ophthalmic pharmaceuticals segment features a variety of treatments for eye conditions, including products like Xipere, Vyzulta, and Lotemax. Bausch + Lomb's commitment to eye health underscores its mission to serve millions globally.

Obagi Medical Products is a specialty pharmaceutical company that develops and markets a variety of topical aesthetic and therapeutic prescription skin care systems. Its product offerings include the Obagi Nu-Derm System, which treats conditions such as fine lines, wrinkles, acne, and hyperpigmentation, as well as the Obagi Condition and Enhance Systems designed for use before and after cosmetic procedures. The company also provides targeted products such as the Obagi-C Rx System, which contains Vitamin C and hydroquinone, and Professional-C serums. Other notable products include ELASTIderm for eye and décolletage treatment, CLENZIderm for acne, and Obagi Rosaclear for rosacea. Obagi Medical Products sells its products through a direct sales force and distribution partners, reaching dermatologists, plastic surgeons, and other physicians focused on skin care both domestically and internationally. Founded in 1988 and headquartered in Irvine, California, the company was previously known as OMP Acquisition Corporation.

Medicis Pharmaceutical is a pharmaceutical and medical product development company that specializes in the creation, manufacturing, and sale of a diverse range of products. The company focuses primarily on areas such as gastroenterology, neurology, and dermatology, particularly in the treatment of dermatological and aesthetic conditions. Its offerings include prescription products designed to address various skin-related issues, including acne, fungal infections, psoriasis, rosacea, seborrheic dermatitis, and skin-structure infections. Through its innovative approach, Medicis Pharmaceutical aims to meet the healthcare needs of patients worldwide.

Eyetech Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for eye diseases. The company has made significant advancements in researching and treating wet age-related macular degeneration, a condition that leads to vision loss. Eyetech's work in this area has been recognized as a breakthrough in ophthalmic treatment. In 2012, Valeant Pharmaceuticals International acquired Eyetech for $22 million, furthering its mission to commercialize antiangiogenic drugs that aim to mitigate the impact of neovascular age-related macular degeneration on patients' vision.

Probiótica Laboratórios Ltda. specializes in the development, manufacturing, and sale of food supplements, primarily targeting the sports nutrition sector. Founded in 1986 and located in Matão, Brazil, the company provides a diverse range of products, including amino acids, protein bars, BCAAs, and various types of proteins, along with items designed for beauty and health, such as creatine and thermogenic products. Probiótica sells its offerings online, making them accessible to a broader audience. As of May 21, 2018, the company operates as a subsidiary of Supley Laboratório de Alimentos e Suplementos Nutricionais Ltda.

iNova Pharmaceuticals is a healthcare company specializing in the development and marketing of over-the-counter and prescription medications. Based in Australia and New Zealand, its product portfolio spans various therapeutic areas such as weight management, pain relief, dermatology, cardiology, respiratory health, allergy, and women's health. The company aims to enhance human health and well-being by providing high-quality pharmaceutical products and services to patients and consumers.

Dermik Laboratories offers therapeutic products to treat acne, actinic keratosis, dermatitis and eczema, insect bites and stings, plant rashes, psoriasis, rosacea, and rough skin; aesthetic products, including HIV facial lipoatrophy products, chemical peels for revitalizing, and skin hydration products; and podiatric products for nail fungus.

PharmaSwiss SA develops and manufactures generics and over-the-counter pharmaceutical products.

Aton Pharma, Inc. is a specialty pharmaceutical company based in Lawrenceville, New Jersey, founded in 2001. The company specializes in treating ophthalmic diseases, orphan conditions, and products for acute care hospitals. Aton Pharma's portfolio includes treatments for metabolic, neurological, and cardiovascular diseases, with a particular emphasis on under-treated conditions such as dry eye. One of its notable products is timolol maleate ophthalmic gel forming solution, designed to manage elevated intraocular pressure in patients suffering from ocular hypertension or open-angle glaucoma. The company serves a diverse array of customers, including patients, caregivers, and healthcare professionals across the United States, the Asia Pacific region, Australia, and other international markets.

Private Formula International is a privately owned medium sized Australian company. It owns and distributes the Dr LeWinns brand through department stores and pharmacies nationally as well as internationally. With 50+ staff based in Australia, the company is a leading innovator of anti-ageing skincare products and treatments providing its consumers with quality products that work at an accessible price point. Private Formula International head office is located at 460 Bay Street, Port Melbourne, Victoria. The company outsources its manufacturing activities through 3 overseas and 4 local suppliers. Private Formula has always been mindful of the potential impact on waste disposals in general and has been concerned on how the global environment changes could impact the future. Private Formula has recently being made aware of a structured organization in this area ie. National Packaging Covenant and fully supports its principles and goals hence, the company is now a signatory of the organization.

Tecnofarma is a Mexican pharmaceutical company that specializes in the production of interchangeable generic medications. It supplies a variety of internal medicines primarily for rheumatology, endocrinology, and cardiology, catering to both government institutions, such as IMSS and ISSSTE, and private label markets. In addition to its generic offerings, Tecnofarma also markets its own line of pharmaceutical products, focusing on meeting the diverse healthcare needs of its clients.

Dow Pharmaceutical Sciences, Inc. engages in the development of topical drug products for pharmaceutical and biotechnology clients.

DermTech, Inc. is a molecular diagnostic company based in La Jolla, California, focused on developing and marketing innovative non-invasive diagnostic tests for skin cancer and related conditions. The company’s flagship product, the Pigmented Lesion Assay (PLA), is a gene expression test designed to rule out melanoma and eliminate the need for surgical biopsies of atypical pigmented lesions. Additionally, DermTech offers the Nevome test, which serves as an adjunctive reflex test for the PLA, along with adhesive skin sample collection kits and gene expression assays targeting various inflammatory pathways. The company is also working on diagnostic products for non-melanoma skin cancer and risk assessment. DermTech primarily markets its products to pathology and oncology practitioners, leveraging advanced qPCR assays that utilize non-invasive adhesive tape biopsy methods to analyze RNA expression levels in skin samples.

DermaTech Pty Ltd is an Australian company specializing in the development, production and distribution of innovative products to address common dermatological conditions such as dry, itchy or sensitive skin, acne, eczema, psoriasis, contact dermatitis, insect bites, skin warts and sunburn.

Coria Laboratories, Ltd. is a privately held pharmaceutical company based in Fort Worth, Texas, specializing in research, development and marketing of branded prescription and over-the-counter dermatology products. The company also provides products for dermatomes, atopic dermatitis, seborrheic dermatitis, contact dermatitis, acne, hyperkeratotic skin disorders, ichthyosis, psoriasis, and keratosis pilaris.

Xcel Pharmaceuticals are a specialty pharmaceutical company focused on prescription products that treat disorders of the central nervous system (CNS). They currently focus on neurology, a segment of the CNS market where a limited number of high-prescribing physicians write a significant number of the prescriptions for neurology products. Their product portfolio consists of four commercial products and two product candidates. Their commercial products include two epilepsy products, Diastat® and Mysoline®, and two migraine products, Migranal® and D.H.E. 45®. Their product candidates include MT 300™, a potential treatment for migraine, and retigabine, a potential treatment for epilepsy. their nationwide field sales organization promotes their products to high-prescribing epilepsy and migraine specialists. Their strategy is to increase prescription demand for Their lead products through targeted sales and marketing efforts, to successfully develop and commercialize Their late-stage development product candidates, to leverage Their CNS presence through the acquisition of additional late-stage development product candidates and commercial products, and to develop enhancements for Their current products. Their corporate infrastructure is designed to support Their field sales organization, to manage Their product development efforts, to identify and pursue the acquisition of additional late-stage development product candidates and commercial products, and to manage Their product enhancement efforts. They have developed valuable relationships with experts and third-party consultants that They intend to utilize for the advancement of late-stage development product candidates, including retigabine, through the development and regulatory approval process. They also utilize third parties to manufacture and distribute Their products and to support Their product development and enhancement efforts.

A leading global eye health organization that is solely focused on protecting, enhancing and restoring people’s eyesight.